Chipscreen Biosciences

Diversified pharma

688321 · SSE · China

Public Market Listing

688321SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Chipscreen Biosciences are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
7Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
HDACSmall molecule
Non-Small Cell Lung CancerBreast CancerDiffuse Large B-Cell LymphomaColorectal CancerNon-Hodgkin Lymphoma
HR+/HER2- Metastatic Breast Cancer, Peripheral T-Cell Lymphoma
Chiglitazar(Bilessglu)
Phase 3
PPAR (pan-agonist)Small molecule
Type 2 Diabetes
Phase 1/2
TYK2Small molecule
Psoriasis
Phase 1
PRMT5 (protein arginine methyltransferase 5), MTA-cooperativeSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
CS32582Phase 1/2Plaque Psoriasis
Est. primary completion 2027-09-18 · NCT07129382 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
ChidamidePhase 3Colorectal Cancer
Est. primary completion 2028-05-31 · NCT06497985 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
ChidamidePhase 3Lymphoma, T-Cell, Peripheral
Est. primary completion 2032-12 · NCT06947967 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 July 2026Topline resultHBI-8000 (chidamide)Phase 3 HBI-8000-303 (NCT04674683) of HBI-8000 plus nivolumab in advanced melanoma met its primary endpoint
HUYABIO International, LLC. · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3————report ↗